Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

New pill orforglipron was associated with a significant reduction in body weight and better cholesterol, triglycerides and blood pressure.

Pharmaceutical giant Eli Lilly said last week that it will raise the U.K. list price of its weight-loss treatment Mounjaro by ...

THE price of Mounjaro is set to soar next month – leaving those using the jabs – and those desperate to slim down concerned at how they will afford the ‘miracle’ injections. Now, many ...

Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

The UK list price of the weight loss drug could nearly triple, but which patients will bear the brunt of the internationally “aligned” cost? Kate Bowie reports In May the Trump administration demanded ...

A late-stage trial shows a daily pill helped people lose 12% of their body weight—without injections. You have two coins that ...

This is an audio transcript of the FT News Briefing podcast episode: ‘What to expect from Jay Powell’s Jackson Hole speech’ Sonja Hutson Good morning from the Financial Times. Today is Wednesday, ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

Viking Therapeutics' stock crashed 40% in early trading on Tuesday after a phase 2 trial of its weight-loss pill showed a ...

Wall Street braced for results from retail giants as rising concerns over inflation cloud the path to an interest rate cut.